|Bid||21.51 x 900|
|Ask||0.00 x 900|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-45.90%|
|Beta (3Y Monthly)||-4.62|
|Expense Ratio (net)||1.11%|
Volatility and uncertainty has resulted in a strong demand for leveraged and inverse-leveraged ETFs as these could fetch outsized returns on quick market turns in a short span.
The indices are well off the early lows Tuesday afternoon, but the question is whether they will manage another strong finish. The automatic buying of any dips smacks of compliancy, but in the age of algorithms, patterns tend to repeat much longer than they have in the past. In the 'old' days, the conventional wisdom was that when a pattern becomes common knowledge, it tended to stop working as traders anticipated it and undermined the movement.
Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action. What Happened Entering Monday, the Direxion Daily S&P Biotech ...
Biotechnology stocks and the related exchange traded funds are off to sizzling starts in 2019. The soaring start to 2019 by the equal-weight S&P Biotechnology Select Industry Index is lifting the fortunes of the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). LABU, one of the largest leveraged biotechnology ETFs, is up more than 45 percent year-to-date, easily making it ne of Direxion's best-performing leveraged bullish ETFs in the month of January.
Biotechnology stocks and exchange traded funds have been slumping since last week's midterm elections and that could be an ominous sign. Ongoing weakness for the equal-weight S&P Biotechnology Select Industry Index benefits the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD). LABD, one of the most heavily traded leveraged biotechnology ETFs, aims to deliver triple the daily inverse returns of the S&P Biotechnology Select Industry Index.